Huminsulin R 40IU/ml Injection contains human insulin at a concentration of 40 international units per milliliter, indicated for the management of diabetes mellitus requiring insulin therapy. This short-acting insulin preparation mimics endogenous insulin, facilitating glucose uptake by peripheral tissues and inhibiting hepatic glucose production, thereby aiding in the control of blood glucose levels. Huminsulin R is primarily used in patients with type 1 diabetes mellitus and in certain cases of type 2 diabetes mellitus when oral hypoglycemic agents are insufficient to achieve glycemic control. The injection is administered subcutaneously, with the onset of action typically occurring within 30 minutes, peak effect between 2 to 4 hours, and duration of action lasting approximately 6 to 8 hours. Dosage and timing should be individualized based on patient-specific factors including blood glucose monitoring results, dietary intake, and physical activity. Caution is advised to avoid hypoglycemia, especially in patients with irregular meal patterns or renal impairment. Common adverse effects include hypoglycemia, injection site reactions, and, rarely, allergic responses. Proper storage and handling are essential to maintain insulin potency. Huminsulin R should be used under medical supervision with regular monitoring to optimize therapeutic outcomes and minimize risks.